TNF Pharmaceuticals Files 8-K on Accountant Change
Ticker: QCLS · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Tnf Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, accountant-change, disclosure
TL;DR
TNF Pharma changed its auditor, filing 8-K on 9/30/24.
AI Summary
On September 30, 2024, TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.) filed an 8-K report. The filing primarily concerns changes in the company's certifying accountant and includes financial statements and exhibits. The company, previously known as Akers Biosciences, Inc., is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing signals a change in the company's auditing firm, which can sometimes indicate shifts in financial reporting or internal controls.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a change in certifying accountant and does not contain information suggesting immediate financial distress or significant operational changes.
Key Players & Entities
- TNF Pharmaceuticals, Inc. (company) — Registrant
- MyMD Pharmaceuticals, Inc. (company) — Former company name
- Akers Biosciences, Inc. (company) — Former company name
- September 30, 2024 (date) — Date of earliest event reported
- 20241004 (date) — Filing date
FAQ
What is the primary reason for TNF Pharmaceuticals, Inc. filing this 8-K?
The primary reasons are changes in the registrant's certifying accountant and the filing of financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on September 30, 2024.
What were TNF Pharmaceuticals, Inc.'s previous names?
The company was formerly known as MyMD Pharmaceuticals, Inc. and Akers Biosciences, Inc.
In which state is TNF Pharmaceuticals, Inc. incorporated?
TNF Pharmaceuticals, Inc. is incorporated in Delaware.
What is the SIC code for TNF Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code is 2835 for IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Filing Stats: 972 words · 4 min read · ~3 pages · Grade level 14 · Accepted 2024-10-04 17:02:48
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TNFA The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex16-1.htm (EX-16.1) — 6KB
- ex16-1_001.jpg (GRAPHIC) — 494KB
- ex16-1_002.jpg (GRAPHIC) — 100KB
- ex16-1_003.jpg (GRAPHIC) — 927KB
- 0001493152-24-039556.txt ( ) — 2319KB
- tnfa-20240930.xsd (EX-101.SCH) — 3KB
- tnfa-20240930_lab.xml (EX-101.LAB) — 33KB
- tnfa-20240930_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TNF PHARMACEUTICALS, INC. Date: October 4, 2024 By: /s/ Joshua Silverman Name: Joshua Silverman Title: Director